author-photo

Alla Lisyanskaya

9

Papers

34

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial.

2021 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Maintenance olaparib for patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation: 5-year follow-up from SOLO1

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Tolerability of maintenance olaparib in newly diagnosed patients with advanced ovarian cancer and a BRCA mutation in the randomized phase III SOLO1 trial

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
1Rucaparib versus chemotherapy in patients with advanced, relapsed ovarian cancer and a deleterious BRCA mutation: efficacy and safety from ARIEL4, a randomized phase III study

2021 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
GOG 3016/ENGOT-cx9: An open-label, multi-national, randomized, phase III trial of cemiplimab, an anti-programmed death (PD)-1, versus investigator's choice (IC) chemotherapy in >= 2 line recurrent or metastatic cervical cancer

2020 Gynecologic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Efficacy of maintenance olaparib for newly diagnosed, advanced ovarian cancer patients with a BRCA mutation: subgroup analysis findings from the SOLO1 trial

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies

2015 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (17)